BioAtla Statistics
Total Valuation
BioAtla has a market cap or net worth of $5.85 million. The enterprise value is $9.98 million.
Important Dates
The last earnings date was Friday, May 15, 2026, after market close.
| Earnings Date | May 15, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BioAtla has 1.66 million shares outstanding. The number of shares has increased by 23.33% in one year.
| Current Share Class | 1.66M |
| Shares Outstanding | 1.66M |
| Shares Change (YoY) | +23.33% |
| Shares Change (QoQ) | +25.56% |
| Owned by Insiders (%) | 7.30% |
| Owned by Institutions (%) | 14.18% |
| Float | 1.37M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.92 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.99 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.15
| Current Ratio | 0.15 |
| Quick Ratio | 0.09 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -134.45% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 415.63% |
| Weighted Average Cost of Capital (WACC) | 4.16% |
| Revenue Per Employee | $48,780 |
| Profits Per Employee | -$1.23M |
| Employee Count | 41 |
| Asset Turnover | 0.09 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -82.74% in the last 52 weeks. The beta is 0.77, so BioAtla's price volatility has been lower than the market average.
| Beta (5Y) | 0.77 |
| 52-Week Price Change | -82.74% |
| 50-Day Moving Average | 5.00 |
| 200-Day Moving Average | 21.51 |
| Relative Strength Index (RSI) | 36.62 |
| Average Volume (20 Days) | 33,232 |
Short Selling Information
The latest short interest is 162,567, so 9.81% of the outstanding shares have been sold short.
| Short Interest | 162,567 |
| Short Previous Month | 147,268 |
| Short % of Shares Out | 9.81% |
| Short % of Float | 11.85% |
| Short Ratio (days to cover) | 4.68 |
Income Statement
In the last 12 months, BioAtla had revenue of $2.00 million and -$50.62 million in losses. Loss per share was -$40.15.
| Revenue | 2.00M |
| Gross Profit | -41.07M |
| Operating Income | -50.40M |
| Pretax Income | -50.62M |
| Net Income | -50.62M |
| EBITDA | -50.09M |
| EBIT | -50.40M |
| Loss Per Share | -$40.15 |
Full Income StatementBalance Sheet
The company has $1.96 million in cash and $6.09 million in debt, with a net cash position of -$4.13 million or -$2.49 per share.
| Cash & Cash Equivalents | 1.96M |
| Total Debt | 6.09M |
| Net Cash | -4.13M |
| Net Cash Per Share | -$2.49 |
| Equity (Book Value) | -37.31M |
| Book Value Per Share | -22.48 |
| Working Capital | -17.60M |
Full Balance SheetCash Flow
| Operating Cash Flow | -37.18M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 310,000 |
| Net Borrowing | 7.13M |
| Free Cash Flow | -37.18M |
| FCF Per Share | -$22.44 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -2,519.95% |
| Pretax Margin | -2,530.85% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
